Presented at the 2020 ASCO Quality Care Symposium, October 9 to October 10, 2020.
Mark A Socinski1; Leigh M Boehmer2
1AdventHealth Cancer Institute, Orlando, FL; 2Association of Community Cancer Centers, Rockville, MD
The rapidly evolving staging system, diagnostic procedures, and treatment options have added complexity to existing treatment algorithms for non-small cell lung cancer (NSCLC). Furthermore, fragmentation of the U.S. healthcare system impedes consistent access to equitable care.
Although multiple aspects of NSCLC management are addressed by existing guidelines, several critical features, including patient education on all aspects of NSCLC (e.g., diagnosis, staging, and treatment), and access to a multidisciplinary team (MDT) care navigator for information on financial aspects of the treatment remain unaddressed.
Consequently, guidance spanning the complete care pathway is lacking.
Defining High-Quality NSCLC Care at U.S. Cancer Centers—via Journal of Clinical Oncology
ASCO Abstract: What Defines Quality Lung Cancer Care?
June 12, 2020
This project is made possible by support from AstraZeneca.